Valuing the broader benefits of dengue vaccination, with a preliminary application to Brazil
- PMID: 23886895
- DOI: 10.1016/j.smim.2013.04.010
Valuing the broader benefits of dengue vaccination, with a preliminary application to Brazil
Abstract
The incidence of dengue has been on the rise since at least the 1960s, bringing greater urgency to the need for a vaccine to prevent the disease. Recent advances suggest that the scientific world is moving closer to an effective dengue vaccine. However, there are concerns that the price of a future vaccine could limit its uptake. High prices, in addition to other challenges, have already weighed negatively in government decisions to include other new vaccines in national immunization programs, e.g., the pneumococcal, rotavirus, and human papillomavirus vaccines. Recent research on the value of vaccination, however, suggests that vaccination confers benefits that are often neglected by traditional economic evaluations. In the case of dengue, commonly overlooked benefits are likely to include reduced spending on outbreak control, averted losses in tourism flows, and avoided productivity losses due to long-term dengue sequelae. Accounting for these and other broader benefits of dengue vaccination could reveal significantly greater economic value and strengthen the case for inclusion of dengue vaccination in national immunization programs. In this article we discuss a framework for the broader value of vaccination and review its application in the context of dengue vaccination for Brazil.
Keywords: Dengue; Economic evaluation; Immunization; Vaccination; Vaccine.
Copyright © 2013 Elsevier Ltd. All rights reserved.
Similar articles
-
Cost-Effectiveness of Dengue Vaccination Programs in Brazil.Am J Trop Med Hyg. 2017 May;96(5):1227-1234. doi: 10.4269/ajtmh.16-0810. Am J Trop Med Hyg. 2017. PMID: 28500811 Free PMC article.
-
Dengue dynamics and vaccine cost-effectiveness in Brazil.Vaccine. 2013 Aug 20;31(37):3957-61. doi: 10.1016/j.vaccine.2013.06.036. Epub 2013 Jun 20. Vaccine. 2013. PMID: 23791696 Free PMC article.
-
Systematic review of health economic evaluation studies of dengue vaccines.Vaccine. 2019 Apr 17;37(17):2298-2310. doi: 10.1016/j.vaccine.2019.03.026. Epub 2019 Mar 22. Vaccine. 2019. PMID: 30910406
-
Current issues in the economics of vaccination against dengue.Expert Rev Vaccines. 2016;15(4):519-28. doi: 10.1586/14760584.2016.1129278. Epub 2016 Jan 4. Expert Rev Vaccines. 2016. PMID: 26642099 Review.
-
Dengue vaccine trial guidelines and role of large-scale, post proof-of-concept demonstration projects in bringing a dengue vaccine to use in dengue endemic areas.Hum Vaccin. 2010 Oct;6(10):802-9. doi: 10.4161/hv.6.10.13018. Epub 2010 Oct 1. Hum Vaccin. 2010. PMID: 20935506 Free PMC article. Review.
Cited by
-
Economic and disease burden of dengue in Mexico.PLoS Negl Trop Dis. 2015 Mar 18;9(3):e0003547. doi: 10.1371/journal.pntd.0003547. eCollection 2015 Mar. PLoS Negl Trop Dis. 2015. PMID: 25786225 Free PMC article.
-
Valuing vaccination.Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):12313-9. doi: 10.1073/pnas.1400475111. Epub 2014 Aug 18. Proc Natl Acad Sci U S A. 2014. PMID: 25136129 Free PMC article. Review.
-
Dengue Dynamics and Vaccine Cost-Effectiveness Analysis in the Philippines.Am J Trop Med Hyg. 2016 Nov 2;95(5):1137-1147. doi: 10.4269/ajtmh.16-0194. Epub 2016 Sep 6. Am J Trop Med Hyg. 2016. PMID: 27601519 Free PMC article.
-
Pars Plana Vitrectomy for a Sub-Internal Limiting Membrane Hemorrhage and Vitreous Hemorrhage Secondary to Dengue Fever: A Case Report.Cureus. 2022 Jun 13;14(6):e25916. doi: 10.7759/cureus.25916. eCollection 2022 Jun. Cureus. 2022. PMID: 35844356 Free PMC article.
-
Realising the broader value of vaccines in the UK.Vaccine X. 2021 Apr 6;8:100096. doi: 10.1016/j.jvacx.2021.100096. eCollection 2021 Aug. Vaccine X. 2021. PMID: 33997762 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical